A Home-based Study Using Mobile Technology to Test Whether BI 1358894 is Effective in People With Depression

  • STATUS
    Recruiting
  • participants needed
    164
  • sponsor
    Boehringer Ingelheim
Send
Updated on 16 February 2024
See if I qualify
antidepressants
depressive disorder
depressive episode
psychiatric disorder
suicidal
scid
suicide
selective serotonin reuptake inhibitors
structured clinical interview
depression
major depressive disorder
serotonin reuptake inhibitors
serotonin and norepinephrine reuptake inhibitors

Summary

The main objectives of this trial are to evaluate the efficacy and safety of oral BI 1358894 compared to placebo over a 6-week treatment period in participants with Major Depressive Disorder (MDD) and with inadequate response to antidepressants (SSRI or SNRI) utilizing a decentralized clinical trial (DCT) model.

Details
Condition Major depression
Age 18years - 65years
Treatment Placebo, BI 1358894
Clinical Study IdentifierNCT04423757
SponsorBoehringer Ingelheim
Last Modified on16 February 2024

Eligibility

 Yes No Not Sure

Inclusion Criteria

Established diagnosis of Major Depressive Disorder, single episode or recurrent, as confirmed at the time of screening by the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders v5 (DSM-5, SCID-5), with a duration of current depressive episode 8 weeks and 12 months at the time of screening visit
Montgomery-sberg Depression Rating Scale (MADRS) total score 22 at screening, as confirmed by a trained rater. In addition, trial participants must have a score of 3 on item number 2 on MADRS
A documented ongoing monotherapy treatment of 8 weeks at the screening visit, with a protocol specified SSRI or SNRI (refer to the ISF) at adequate dose (at least minimum effective dose as per prescribing information and as confirmed per detectable drug levels in the screening blood sampling)
Male and female participants, 18 to 65 years of age, both inclusively at the time of consent
Women of child-bearing potential (WOCBP)2 able and willing to use two methods of contraception, which include one highly effective method of birth control per ICH M3 (R2) that results in a low failure rate of less than 1%, plus one barrier method
Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial
Able to communicate well, and to understand and comply with trial requirements

Exclusion Criteria

Per DSM-5, had ever met diagnostic criteria for schizophrenia, schizoaffective disorder, schizophreniform disorder, bipolar disorder, delusional disorder or MDD with psychotic features as assessed by the Structured Clinical Interview for DSM 5 (SCID-5) at the time of screening
Diagnosis of any other mental disorder (in addition to those as described in Exclusion Criterion #1) that was the primary focus of treatment within 6 months prior to screening or at baseline (as per clinical discretion of the investigator)
Diagnosis with antisocial, paranoid, schizoid or schizotypal personality disorder as per DSM-5 criteria, at the time of screening visit. Any other personality disorder at screening visit that significantly affects current psychiatric status and likely to impact trial participation, as per the judgement of investigator
Diagnosis of a substance related disorder within 3 months prior to screening visit (with exception of caffeine and tobacco)
History of seizure disorders, stroke, brain tumor or any other major neurological illness that can impact participation in the trial
History of more than 2 unsuccessful monotherapy treatments (at adequate dosage and duration, per local prescribing information of the product) with an approved antidepressant medication for the current ongoing major depressive episode. These include ongoing monotherapy treatment with a protocol specified SSRI or SNRI as described in Inclusion Criterion #3
Any suicidal behavior in the past 12 months prior to screening (per investigator judgement including an actual attempt, interrupted attempt, aborted attempt, or preparatory acts or behaviour)
Any suicidal ideation of type 4 or 5 in the Columbia Suicide Severity Rating Scale (CSSRS) in the past 3 months prior to screening or at screening or baseline visit (i.e. active suicidal thought with method and intent but without specific plan, or active suicidal thought with method, intent and plan)
Further exclusion criteria apply
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

antidepressants
depressive disorder
depressive episode
psychiatric disorder
suicidal
scid
suicide
selective serotonin reuptake inhibitors
structured clinical interview
depression
major depressive disorder
serotonin reuptake inhibitors
serotonin and norepinephrine reuptake inhibitors

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.